CoChat
Sign Up
Cited by 133Chronic Lymphocytic Leukemia ResearchAcute Myeloid Leukemia ResearchLymphoma Diagnosis and Treatment

Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL

Open access
Kadri, Sabah, Lee, Jimmy, Fitzpatrick, Carrie, Galanina, Natalie, Sukhanova, Madina, Venkataraman, Girish, Sharma, Shruti, Long, Brad +16 more·2017·Blood Advances
DOI 10.1182/bloodadvances.2016003632PMC PMC5728051
Open this paper in CoChat — free accountOpen PDF

Abstract

Key Points: Del(18p), together with del(17p)/TP53 mutations, is present at a high frequency before ibrutinib treatment. BTK mutations drive ibrutinib relapse, but del(17p)/TP53 mutations may be dispensable.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/bloodadvances.2016003632

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Mutations in PLCγ2 and/or Btk have been reported in 11 to 90% of cases of Ibrutinib-refractory CLL.

    “Mutations in PLCγ2 and/or Btk have been reported in 11 to 90% cases of Ibrutinib-refractory CLL, further underscoring the importance of better understanding the process by which the partnership of Btk and PLCγ2 drives CLL disease progression (122, 123, 124, 125, 126).”

    From The role of PLCγ2 in immunological disorders, cancer, and neurodegeneration (2021) · cites this paper as [124]

    The Discussion reports that, among 28 patients with CLL progression after ibrutinib relapse, 71% had BTK mutations and 11% had PLCG2 mutations. It does not report 90% for either gene or for the two combined; the reported counts total 23 of 28 patients (82%). (LLM, conf=0.87)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 39

  1. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42.
  2. Treon SP, Tripsas CK, Yang G, et al. A prospective multicenter study of the Bruton's tyrosine kinase inhibitor ibrutinib in patients with relapsed or refractory Waldenstrom's macroglobulinemia. Blood. 2013;122(21):251.
  3. Burger JA, Keating MJ, Wierda WG, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single- arm, phase 2 study. Lancet Oncol. 2014;15(10):1090-1099.
  4. Jain P, Keating M, Wierda W, et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015;125(13): 2062-2067.
  5. Ahn IE, Underbayev C, Albitar A, et al. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood. 2017;129(11):1469-1479.
  6. Mato AR, Nabhan C, Barr PM, et al. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. Blood. 2016; 128(18):2199-2205.
  7. Zhang SQ, Smith SM, Zhang SY, Lynn Wang Y. Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. Br J Haematol. 2015;170(4):445-456.
  8. Herman SE, Mustafa RZ, Gyamfi JA, et al. Ibrutinib inhibits BCR and NF-kB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. Blood. 2014;123(21):3286-3295.
  9. Cheng S, Ma J, Guo A, et al. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia. 2014;28(3): 649-657.
  10. Guo A, Lu P, Galanina N, et al. Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib. Oncotarget. 2016;7(4):4598-4610.
  11. Herman SE, Sun X, McAuley EM, et al. Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy. Leukemia. 2013;27(12):2311-2321.
  12. Burger JA, Li KW, Keating MJ, et al. Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib. JCI Insight. 2017;2(2):e89904.
  13. Furman RR, Cheng S, Lu P, et al. Ibrutinib resistance in chronic lymphocytic leukemia [published correction appears in N Engl J Med. 2014;370(26): 2547].
  14. N Engl J Med. 2014;370(24):2352-2354.
  15. Burger JA, Landau DA, Taylor-Weiner A, et al. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016;7:11589.
  16. Kadri S, Long BC, Mujacic I, et al. Clinical validation of a next-generation sequencing genomic oncology panel via cross-platform benchmarking against established amplicon sequencing assays. J Mol Diagn. 2017;19(1):43-56.
  17. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30(15):2114-2120.
  18. Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. https://arxiv.org/pdf/1303.3997v1.pdf. Accessed 15 October 2016. · arXiv
  19. Mose LE, Wilkerson MD, Hayes DN, Perou CM, Parker JS. ABRA: improved coding indel detection via assembly-based realignment. Bioinformatics. 2014;30(19):2813-2815.
  20. Li H, Handsaker B, Wysoker A, et al; 1000 Genome Project Data Processing Subgroup. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009;25(16):2078-2079.
  21. Robinson JT, Thorvaldsd óttir H, Winckler W, et al. Integrative genomics viewer. Nat Biotechnol. 2011;29(1):24-26.
  22. Thorvaldsd óttir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform. 2013;14(2):178-192.
  23. Sharma S, Galanina N, Guo A, et al. Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL. Oncotarget. 2016;7(42): 68833-68841.
  24. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med. 1998;17(8):873-890.
  25. Thompson PA, O'Brien SM, Wierda WG, et al. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer. 2015;121(20):3612-3621.
  26. Puente XS, Be à S, Vald és-Mas R, et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature. 2015;526(7574):519-524.
  27. Landau DA, Tausch E, Taylor-Weiner AN, et al. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015;526(7574):525-530.
  28. Stilgenbauer S, Schnaiter A, Paschka P, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014;123(21):3247-3254.
  29. Baliakas P, Hadzidimitriou A, Sutton LA, et al; European Research Initiative on CLL (ERIC). Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia. 2015;29(2):329-336.
  30. Houldsworth J, Guttapalli A, Thodima V, et al. Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2014;55(4):920-928.
  31. Chigrinova E, Rinaldi A, Kwee I, et al. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood. 2013;122(15):2673-2682.
  32. Fabbri G, Khiabanian H, Holmes AB, et al. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. J Exp Med. 2013;210(11):2273-2288.
  33. Cheng S, Guo A, Lu P, Ma J, Coleman M, Wang YL. Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors. Leukemia. 2015;29(4):895-900.
  34. Lohr JG, Stojanov P, Lawrence MS, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci USA. 2012;109(10):3879-3884.
  35. Landau DA, Carter SL, Getz G, Wu CJ. Clonal evolution in hematological malignancies and therapeutic implications. Leukemia. 2014;28(1):34-43.
  36. Rossi D, Spina V, Deambrogi C, et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood. 2011;117(12):3391-3401.
  37. Yu L, Kim HT, Kasar SN, et al. Survival of del17p CLL depends on genomic complexity and somatic mutation. Clin Cancer Res. 2017;23(3):735-745.
  38. Volkert S, Kohlmann A, Schnittger S, Kern W, Haferlach T, Haferlach C. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome. Genes Chromosomes Cancer. 2014;53(5):402-410.
  39. Ahn IE, Albitar A, Underbayev C, et al. Integrated analysis of ibrutinib resistance in chronic lymphocytic leukemia [abstract] In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 16-20 April 2016; New Orleans, LA. Philadelphia, PA: AACR. Cancer Res. 2016; 76(14 Suppl). Abstract 292.

Cited by

Sorted by citations

Authors
Kadri, S., Lee, J., Fitzpatrick, C., Galanina, N., Sukhanova, M., Venkataraman, G., Sharma, S., Long, B., Petras, K., Theissen, M., Ming, M., Kobzev, Y., Kang, W., Guo, A., Wang, W., Niu, N., Weiner, H., Thirman, M., Stock, W., Smith, S. M., Nabhan, C., Segal, J. P., Lu, P., & Wang, Y. L.
Affiliations
  • Department of Pathology,
  • Department of Medicine, and
  • University of Chicago (US)
  • Cardinal Health (United States) (US)
Corresponding author
  • Kadri, Sabah
  • Lee, Jimmy
  • Fitzpatrick, Carrie
ORCID
Venue
Blood Advances
Publisher
American Society of Hematology
Published
2017-05-02
Volume
1
Issue
12
Pages
715-727
ISSN
  • 2473-9529 (ISSN-L)
  • 2473-9537
DOI
10.1182/bloodadvances.2016003632
PMC
PMC5728051
OpenAlex
W2610704467
Cited by
133
References
5
Citations by year
2026: 3 · 2025: 13 · 2024: 11 · 2023: 15 · 2022: 16 · 2021: 30 · 2020: 16 · 2019: 14 · 2018: 13 · 2017: 2
FWCI
7.07
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Blood Advances (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Health Sciences › Medicine › Genetics › Chronic Lymphocytic Leukemia Research
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
Keywords
clonal evolution, chronic lymphocytic leukemia, Richter transformation, BTK inhibitor resistance, somatic mutations, genomic abnormalities, leukemia progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review